Samy I. McFarlane
Dr. McFarlane is Distinguished Teaching Professor of Medicine/Endocrinology and Associate Dean at SUNY-Downstate, Health Sciences University, Brooklyn, New York, USA. He has extensive experience in clinical and translational research and served as the PI for the largest center in North America in the landmark Diabetes Reduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. He is the author of more than 400 publications with more than 10,000 citations and an h-index of 46. He also has 270 highly influential citations to his credit, including those in major guidelines by the American Heart Association (AHA), such as stroke guidelines (2018 and 2019), the Scientific Statement from the AHA on Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation 2020, and the 2021 SHNE/HRS/EHRA/APHRS Expert Collaborative Statement. He is also the editor of several books on diabetes, hypertension, cardiovascular disease, and related topics. Dr. McFarlane is a three-term member of the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK) and served twice as chair of the NIH-NIDDK U01 committee. He also served as chair of the clinical sub-committee of the National Kidney Foundation (NKF) Kidney Early Evaluation Program. Locally, he held several leadership positions including Medical Director of Clinical Research and Program Director and Chief of Endocrinology. He also served as District President of the American College of Physicians. Dr. McFarlane is the recipient of numerous awards and honors including recognition from the United States Army, the US Congress, and the Gold Foundation for Humanism in Medicine.